RU2013141559A - Способ ингибирования клеток опухоли гамартомы - Google Patents
Способ ингибирования клеток опухоли гамартомы Download PDFInfo
- Publication number
- RU2013141559A RU2013141559A RU2013141559/04A RU2013141559A RU2013141559A RU 2013141559 A RU2013141559 A RU 2013141559A RU 2013141559/04 A RU2013141559/04 A RU 2013141559/04A RU 2013141559 A RU2013141559 A RU 2013141559A RU 2013141559 A RU2013141559 A RU 2013141559A
- Authority
- RU
- Russia
- Prior art keywords
- syndrome
- represents hydrogen
- compound
- trifluoromethyl
- halogen
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 30
- 208000002927 Hamartoma Diseases 0.000 title claims abstract 25
- 210000004881 tumor cell Anatomy 0.000 title claims abstract 17
- 230000002401 inhibitory effect Effects 0.000 title claims abstract 14
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 45
- 239000001257 hydrogen Substances 0.000 claims abstract 45
- 150000001875 compounds Chemical class 0.000 claims abstract 28
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 26
- 229910052736 halogen Chemical group 0.000 claims abstract 20
- 150000002367 halogens Chemical group 0.000 claims abstract 20
- 150000003839 salts Chemical class 0.000 claims abstract 20
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract 20
- 230000035755 proliferation Effects 0.000 claims abstract 16
- 150000002431 hydrogen Chemical class 0.000 claims abstract 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 10
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims abstract 9
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims abstract 9
- 208000029522 neoplastic syndrome Diseases 0.000 claims abstract 9
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 claims abstract 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 5
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims abstract 5
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 claims 15
- 208000012609 Cowden disease Diseases 0.000 claims 8
- 201000002847 Cowden syndrome Diseases 0.000 claims 8
- 201000007815 Bannayan-Riley-Ruvalcaba syndrome Diseases 0.000 claims 4
- 208000013148 Cowden syndrome 1 Diseases 0.000 claims 4
- 208000007531 Proteus syndrome Diseases 0.000 claims 4
- 201000010917 PTEN hamartoma tumor syndrome Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161441896P | 2011-02-11 | 2011-02-11 | |
| US61/441,896 | 2011-02-11 | ||
| PCT/US2012/024440 WO2012109423A1 (en) | 2011-02-11 | 2012-02-09 | Method of inhibiting hamartoma tumor cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013141559A true RU2013141559A (ru) | 2015-03-20 |
Family
ID=45809596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013141559/04A RU2013141559A (ru) | 2011-02-11 | 2012-02-09 | Способ ингибирования клеток опухоли гамартомы |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20140309221A1 (enExample) |
| EP (1) | EP2673268A1 (enExample) |
| JP (1) | JP2014505107A (enExample) |
| KR (1) | KR20140063509A (enExample) |
| CN (1) | CN103476765A (enExample) |
| AU (1) | AU2012214413A1 (enExample) |
| BR (1) | BR112013020159A2 (enExample) |
| CA (1) | CA2826387A1 (enExample) |
| MX (1) | MX2013009256A (enExample) |
| RU (1) | RU2013141559A (enExample) |
| WO (1) | WO2012109423A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| JP6026544B2 (ja) | 2011-09-27 | 2016-11-16 | ノバルティス アーゲー | 変異体ｉｄｈの阻害剤としての３−ピリミジン−４−イル−オキサゾリジン−２−オン類 |
| UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
| US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
| CN103012284A (zh) * | 2012-12-26 | 2013-04-03 | 无锡捷化医药科技有限公司 | 一种2-氨基-5-溴嘧啶类化合物的制备方法 |
| GEP201706699B (en) | 2013-03-14 | 2017-07-10 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| CA2944697C (en) | 2014-04-22 | 2022-07-19 | Universitaet Basel | Manufacturing process for triazine, pyrimidine and pyridine derivatives |
| CN105001151B (zh) * | 2015-08-28 | 2017-07-14 | 苏州明锐医药科技有限公司 | 布帕尼西中间体及其制备方法 |
| JP7118509B2 (ja) * | 2016-05-18 | 2022-08-16 | トルク アーゲー | 皮膚病変の治療 |
| EP3458035A1 (en) * | 2016-05-18 | 2019-03-27 | PIQUR Therapeutics AG | Treatment of skin lesions |
| CN106905294A (zh) * | 2016-07-08 | 2017-06-30 | 苏州科睿思制药有限公司 | 5‑[2,6‑二(4‑吗啉基)‑4‑嘧啶基]‑4‑(三氟甲基)‑2‑吡啶胺的晶型及其制备方法 |
| CN106632443B (zh) * | 2016-11-23 | 2022-06-17 | 山东友帮生化科技有限公司 | 一种2-氨基嘧啶-5-硼酸频哪酯硼酸盐的合成方法 |
| RU2020115351A (ru) * | 2017-11-23 | 2021-12-23 | Пикур Терапьютикс Аг | Лечение кожных заболеваний |
| CN114213340B (zh) | 2022-02-22 | 2022-06-07 | 北京蓝晶微生物科技有限公司 | 2,4-二氨基嘧啶氧化物的制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| CN102548970B (zh) * | 2009-07-02 | 2015-11-25 | 赛诺菲 | 新型(6-氧代-1,6-二氢嘧啶-2-基)酰胺衍生物、其制备方法以及其作为akt(pkb)磷酸化抑制剂的医药用途 |
-
2012
- 2012-02-09 RU RU2013141559/04A patent/RU2013141559A/ru not_active Application Discontinuation
- 2012-02-09 JP JP2013553557A patent/JP2014505107A/ja not_active Withdrawn
- 2012-02-09 US US13/984,422 patent/US20140309221A1/en not_active Abandoned
- 2012-02-09 BR BR112013020159A patent/BR112013020159A2/pt not_active IP Right Cessation
- 2012-02-09 MX MX2013009256A patent/MX2013009256A/es not_active Application Discontinuation
- 2012-02-09 AU AU2012214413A patent/AU2012214413A1/en not_active Abandoned
- 2012-02-09 EP EP12707171.0A patent/EP2673268A1/en not_active Withdrawn
- 2012-02-09 CN CN201280013673XA patent/CN103476765A/zh active Pending
- 2012-02-09 WO PCT/US2012/024440 patent/WO2012109423A1/en not_active Ceased
- 2012-02-09 CA CA2826387A patent/CA2826387A1/en not_active Abandoned
- 2012-02-09 KR KR1020137023617A patent/KR20140063509A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20140309221A1 (en) | 2014-10-16 |
| KR20140063509A (ko) | 2014-05-27 |
| AU2012214413A1 (en) | 2013-08-22 |
| JP2014505107A (ja) | 2014-02-27 |
| EP2673268A1 (en) | 2013-12-18 |
| WO2012109423A1 (en) | 2012-08-16 |
| BR112013020159A2 (pt) | 2016-11-08 |
| MX2013009256A (es) | 2013-12-09 |
| CN103476765A (zh) | 2013-12-25 |
| CA2826387A1 (en) | 2012-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013141559A (ru) | Способ ингибирования клеток опухоли гамартомы | |
| JP2014505107A5 (enExample) | ||
| UY30809A1 (es) | Derivados de n-[3-[4-fenil)piperidin-1-carbonil]fenil]sulfonamidas sustituidas, procesos de preparacion y aplicaciones | |
| RU2011151835A (ru) | Пиразолопиримидины и родственные гетероциклы как ингибиторы киназ | |
| GEP20156389B (en) | Oxazolidin-2-one compounds and their usage as pi3ks inhibitors | |
| JP2014511892A5 (enExample) | ||
| JP2013510123A5 (enExample) | ||
| EA201100971A1 (ru) | Производные пиримидининдола для лечения злокачественного новообразования | |
| JP2008535902A5 (enExample) | ||
| NZ700761A (en) | Salt form of a human histone methyltransferase ezh2 inhibitor | |
| PH12015500719A1 (en) | Gdf-8-inhibitors | |
| EA201490673A1 (ru) | Производные пирролопиримидина и пурина | |
| JP2013531029A5 (enExample) | ||
| EA201201680A1 (ru) | Морфолинопиримидины и их применение в терапии | |
| NZ598085A (en) | Methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid | |
| RU2010128512A (ru) | Гетероциклические ингибиторы мек и способы их применения | |
| TW200833663A (en) | Therapeutic agents | |
| RU2014152790A (ru) | Пирролопиразоновые ингибиторы танкиразы | |
| JP2017514809A5 (enExample) | ||
| RU2013127655A (ru) | Фармацевтическая комбинация паклитаксела и ингибитора cdk | |
| RU2013150861A (ru) | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний | |
| NZ607580A (en) | N-heteroaryl compounds | |
| EA201391337A1 (ru) | Ингибиторы hsp90 | |
| RU2013108348A (ru) | Конденсированные гетероарилы и их применение | |
| JP2011521938A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20160316 |